S1 Fig -

(A) Serum neutralization after 2 (post-2) and 3 (post-3) immunization of each animal. Numbers indicate ID50. (B) Cross-competition binding of biotinylated NHP mAbs to 16055 NFL TD CC trimers (His-captured) in the presence of non-biotinylated mAb competitors (left column) as assessed by ELISA. Percent competition was determined based on the absorbance measured with 200 μg/ml competitor or 10 μg/ml NHP mAbs present and 0% competition being the absorbance measured with no competitor present. (C) Binding of NHP mAbs to 16055 gp120 V loop variants as measured by ELISA: WT, wild-type; ΔV1V2 (Δ126–197); ΔV1 (≥Δ134–153; ΔV2 (Δ159–193); +, binding;–, no binding. (D) Specificity and relative neutralization potencies of NHP mAbs against a panel of V2 point mutant viruses (residues 182–187 were each mutated to Ala, except for N187Q) compared to wild type. Enhanced potencies as measured by IC50 values are highlighted in red (> 10-fold) and pink (10-fold); decreased potencies in grey, knock-out (KO) mutations in dark grey.

(TIF)